DK1492440T3 - Fremgangsmåde til opnåelse af en diagnose og prognose for maligne sygdomme - Google Patents

Fremgangsmåde til opnåelse af en diagnose og prognose for maligne sygdomme

Info

Publication number
DK1492440T3
DK1492440T3 DK03728350T DK03728350T DK1492440T3 DK 1492440 T3 DK1492440 T3 DK 1492440T3 DK 03728350 T DK03728350 T DK 03728350T DK 03728350 T DK03728350 T DK 03728350T DK 1492440 T3 DK1492440 T3 DK 1492440T3
Authority
DK
Denmark
Prior art keywords
diagnosis
prognosis
obtaining
malignant diseases
cell
Prior art date
Application number
DK03728350T
Other languages
Danish (da)
English (en)
Inventor
Paula J Bates
Donald M Miller
John O Trent
Xiaohua Xu
Original Assignee
Univ Louisville Res Found
Paula J Bates
Donald M Miller
John O Trent
Xiaohua Xu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found, Paula J Bates, Donald M Miller, John O Trent, Xiaohua Xu filed Critical Univ Louisville Res Found
Application granted granted Critical
Publication of DK1492440T3 publication Critical patent/DK1492440T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DK03728350T 2002-04-08 2003-04-08 Fremgangsmåde til opnåelse af en diagnose og prognose for maligne sygdomme DK1492440T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/118,854 US7541150B2 (en) 2002-04-08 2002-04-08 Method for the diagnosis and prognosis of malignant diseases
PCT/US2003/010745 WO2003086174A2 (en) 2002-04-08 2003-04-08 A new method for the diagnosis and prognosis of malignant diseases

Publications (1)

Publication Number Publication Date
DK1492440T3 true DK1492440T3 (da) 2008-09-22

Family

ID=28789881

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03728350T DK1492440T3 (da) 2002-04-08 2003-04-08 Fremgangsmåde til opnåelse af en diagnose og prognose for maligne sygdomme

Country Status (10)

Country Link
US (1) US7541150B2 (de)
EP (1) EP1492440B8 (de)
JP (3) JP4841109B2 (de)
AT (1) ATE398138T1 (de)
AU (1) AU2003234694B8 (de)
CA (1) CA2490724C (de)
DE (1) DE60321552D1 (de)
DK (1) DK1492440T3 (de)
ES (1) ES2307936T3 (de)
WO (1) WO2003086174A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178161A1 (en) * 1999-04-08 2011-07-21 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
CA2370000A1 (en) * 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
CA2476764A1 (en) * 2002-02-19 2003-08-28 Syntherica Corporation Compositions and methods for surrogate antibody modulation of an immune response and transport
US7544767B2 (en) * 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US20040132049A1 (en) * 2002-06-26 2004-07-08 Bates Paula J. Method for the detection of apoptosis
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
CN1969189B (zh) * 2004-06-14 2012-03-21 协和梅迪克斯株式会社 非特异性反应被抑制的可溶性白介素-2受体免疫学测定方法和试剂
US20060073534A1 (en) * 2004-10-05 2006-04-06 The University Of Georgia Research Foundation, Inc Method for cleaving and deglycosylating antibodies to promote ligand binding
CN102539734B (zh) * 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
US20090226914A1 (en) * 2007-12-31 2009-09-10 Bates Paula J Methods and products to target, capture and characterize stem cells
CN102770529B (zh) 2009-11-17 2018-06-05 Musc研究发展基金会 针对人核仁素的人单克隆抗体
CN101782573B (zh) * 2010-01-11 2014-09-10 天津师范大学 检测重金属胁迫下核仁c23蛋白质定位的免疫荧光方法
EP3450979A3 (de) 2010-03-17 2019-04-24 The Regents of The University of Michigan Verwendung von phagenepitopen zur profilierung einer immunreaktion
WO2011120015A2 (en) * 2010-03-26 2011-09-29 Armune Biosciences, Inc. Method and system of particle-coupled phage epitope
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
US20130023479A1 (en) 2011-07-22 2013-01-24 Protgen Ltd. Use of nucleolin as a biomarker for lymphangiogenesis in cancer prognosis and therapy
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
RU2728964C2 (ru) 2016-02-19 2020-08-03 Сива Корпорейшн Способ и композиция для лечения рака, уничтожения метастатических раковых клеток и профилактики метастазов рака, используя антитела к конечным продуктам повышенного гликирования ( AGE)
WO2017181049A1 (en) * 2016-04-15 2017-10-19 Charlestonpharma, Llc Anti-nucleolin agents
US20190192686A1 (en) 2016-08-02 2019-06-27 The University Of Louisville Research Foundation, Targeted nanodroplet emulsions for treating cancer
JP2020515634A (ja) * 2017-03-20 2020-05-28 キャンサー、セラピューティックス、ラボラトリーズ、インコーポレイテッドＣａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． 腫瘍壊死を標的とする組成物及び方法
US20230181769A1 (en) 2019-09-10 2023-06-15 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-peg-conjugated nanoparticles
CN115135665A (zh) * 2019-12-30 2022-09-30 俄亥俄州国家创新基金会 包含细胞穿透肽的环状蛋白
US20210299156A1 (en) 2020-03-28 2021-09-30 Qualigen Inc. Methods of inhibiting or treating coronavirus infection, and methods for delivering an anti-nucleolin agent

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4474892A (en) * 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US4665897A (en) * 1984-05-25 1987-05-19 Lemelson Jerome H Composition and method for detecting and treating cancer
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5192660A (en) * 1989-04-24 1993-03-09 The United States Of America As Represented By The Department Of Health And Human Services ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids
AU635008B2 (en) * 1989-12-13 1993-03-11 Genelabs Diagnostics Pte Ltd Analytical apparatus and method for automated blot assay
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5736348A (en) * 1990-11-28 1998-04-07 Fundacao Oswaldo Cruz (Fiocruz) Method for the immunological diagnosis of Chagas' Disease using recombinant antigens
JPH05244988A (ja) * 1992-03-04 1993-09-24 Green Cross Corp:The 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
JPH07242566A (ja) 1994-03-01 1995-09-19 Kirin Brewery Co Ltd 免疫抑制剤
US6096532A (en) * 1995-06-07 2000-08-01 Aastrom Biosciences, Inc. Processor apparatus for use in a system for maintaining and growing biological cells
US5567660A (en) * 1995-09-13 1996-10-22 Taiwan Semiconductor Manufacturing Company Ltd Spin-on-glass planarization by a new stagnant coating method
CA2240494C (en) 1995-12-15 2007-03-13 Lloyd G. Mitchell Therapeutic molecules generated by trans-splicing
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
KR20080059467A (ko) 1996-12-03 2008-06-27 아브게닉스, 인크. 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
CA2284084A1 (en) 1997-03-12 1998-09-17 Institut Pasteur A novel cell surface receptor for hiv retroviruses, therapeutic and diagnostic uses
JP2001523977A (ja) * 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
CA2293632C (en) * 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6339075B1 (en) * 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
AU6053898A (en) 1997-08-04 1999-02-22 Burnham Institute, The A cell-free system of mitochondria-dependent apoptosis, and methods of use ther eof
US6325785B1 (en) * 1997-08-14 2001-12-04 Sherwood Services Ag Sputum trap manifold with nested caps
US5925334A (en) * 1997-08-27 1999-07-20 Rubin; Bruce K. Use of surface active agents to promote mucus clearance
US5932475A (en) * 1997-12-12 1999-08-03 Incyte Pharmaceuticals, Inc. Human nucleolin-like protein
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6306404B1 (en) * 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
AU6162999A (en) * 1998-09-24 2000-04-10 Promega Corporation Apoptosis marker antibodies and methods of use
CA2370000A1 (en) * 1999-04-08 2000-10-19 Uab Research Foundation Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
WO2000063250A1 (en) 1999-04-15 2000-10-26 Merck Frosst Canada & Co. Antibodies that recognize app cleaved by caspases and methods of use
US6165786A (en) 1999-11-03 2000-12-26 Isis Pharmaceuticals, Inc. Antisense modulation of nucleolin expression
EP1229328B1 (de) 1999-11-08 2007-06-20 Eisai Co., Ltd. Verfahren zum Nachweis von Zelltod mittels Cytochrom C.
JP2001213804A (ja) * 2000-01-31 2001-08-07 Chugai Pharmaceut Co Ltd 抗組織因子抗体の複合体
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
JP2004505894A (ja) 2000-06-02 2004-02-26 ユニバーシティー　オブ　コネティカット　ヘルス　センター 免疫療法のためのα（２）マクログロブリンと抗原分子との複合体
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
DE10037861A1 (de) 2000-08-01 2002-02-14 Max Delbrueck Centrum Mittel zur Therapie maligner Erkrankungen
AU2001284703B2 (en) 2000-08-03 2007-03-22 Therapeutic Human Polyclonals Inc. Production of humanized antibodies in transgenic animals
DE10059821A1 (de) 2000-12-01 2002-06-13 Clariant Gmbh Tensidfreie kosmetische, dermatologische und pharmazeutische Mittel
JP3676991B2 (ja) 2001-07-05 2005-07-27 松下電器産業株式会社 無線通信装置及び無線通信方法
US20050130117A1 (en) 2001-10-03 2005-06-16 Davis Cong L. Modulators of lymphocyte activation and migration
WO2003087124A2 (en) 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US20040132049A1 (en) 2002-06-26 2004-07-08 Bates Paula J. Method for the detection of apoptosis

Also Published As

Publication number Publication date
US7541150B2 (en) 2009-06-02
EP1492440A4 (de) 2005-08-24
US20030194754A1 (en) 2003-10-16
WO2003086174A3 (en) 2004-09-23
JP2013100295A (ja) 2013-05-23
JP5712198B2 (ja) 2015-05-07
EP1492440B8 (de) 2008-07-16
DE60321552D1 (de) 2008-07-24
WO2003086174A2 (en) 2003-10-23
CA2490724A1 (en) 2003-10-23
JP2011246467A (ja) 2011-12-08
CA2490724C (en) 2010-12-21
EP1492440B1 (de) 2008-06-11
JP2005526968A (ja) 2005-09-08
EP1492440A2 (de) 2005-01-05
ATE398138T1 (de) 2008-07-15
AU2003234694A1 (en) 2003-10-27
ES2307936T3 (es) 2008-12-01
JP4841109B2 (ja) 2011-12-21
AU2003234694B2 (en) 2008-05-15
AU2003234694B8 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
DK1492440T3 (da) Fremgangsmåde til opnåelse af en diagnose og prognose for maligne sygdomme
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
DK1877559T3 (da) Mitochondrial mutationer og omarrangeringer som et diagnostisk værktøj for detektion af soleksponering, prostatacancer og andre cancertyper
NO20074474L (no) Antistoffer som binder til EPHA2 og fremgangsmate for anvendelse derav
TWI317811B (de)
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
DK3489689T3 (da) Bestemmelse af neutrofil gelatinase-associeret lipocalin (NGAL) som diagnostisk markør for nyresygdomme
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
ATE539170T1 (de) Abschätzung und verringerung des risikos von graft-versus-host-reaktion
DK1092155T3 (da) Fremgangsmåde til tidlig diagnose af carcinomer
DK1940918T3 (da) Dimercaptanterminerede polythioetherpolymerer og fremgangsmåder til at fremstille og anvende samme
WO2006012646A3 (en) Amacr cancer markers
MY150234A (en) Predictive markers for ovarian cancer
ATE509033T1 (de) Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
GB2424480A (en) Prostate stem cell
DK1869475T3 (da) In vitro metode til samtidig detektering og identifikation af antibiotika i forskellige klasser og et tilsvarende diagnosekit
DE60331310D1 (de) Verfahren zum apoptosenachweis
ATE456666T1 (de) Verfahren zur auswertung von ribonukleotidsequenzen
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
CY1114386T1 (el) Διαγνωση καρκινου του προστατη
WO2008073895A3 (en) Methods and devices for testing saliva
DE502005004900D1 (de) Trägerplatte zur durchführung funktioneller tests an biologischen zellen sowie verfahren zur beschichtung der trägerplatte
ATE416262T1 (de) Einen grössenausschlussschritt verwendendes verbessertes bisulfit-verfahren
WO2007075672A3 (en) Prognostic cancer markers
WO2005033133A3 (en) Polynucleotides encoding erbb-2 polypeptides and kits and methods using same